Levetiracetam Treatment of Neonatal Seizures: Safety and Efficacy Phase II Study
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
LEVNEONAT is a multicentre French clinical trials with the aim to develop new treatment
strategies for the treatment of neonatal seizures using Levetiracetam. The purpose of this
study is to determine the correct dosing, safety and efficacy for intravenous levetiracetam
as first line treatment in term newborn babies with seizures in hypoxic-ischemic
encephalopathy context. This new anticonvulsivant drug is a promising treatment for seizures
in newborns.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Tours
Collaborators:
Amiens University Hospital Assistance Publique - Hôpitaux de Paris European Georges Pompidou Hospital Rennes University Hospital